Far From Checkmate: Gastrointestinal Neoplasia Risk in Patients With Pathogenic Variants in CHEK2

被引：1
|
作者：
Sommovilla, Joshua [1 ,2 ]
Burke, Carol [1 ,2 ,3 ]
Liska, David [1 ,3 ]
机构：
[1] Cleveland Clin, Digest Dis & Surg Inst, Dept Colorectal Surg, Cleveland, OH USA
[2] Cleveland Clin, Sanford R Weiss MD Ctr Hereditary Colorectal Neopl, Digest Dis Inst, Dept Colorectal Surg, Cleveland, OH USA
[3] Cleveland Clin, Digest Dis & Surg Inst, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH USA
来源：
DISEASES OF THE COLON & RECTUM | 2024年 / 67卷 / 10期
关键词：
BREAST-CANCER; SUSCEPTIBILITY;
D O I：
10.1097/DCR.0000000000003449
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1225 / 1226
页数：2
相关论文
共 50 条
  • [1] CHEK2 Pathogenic Germline Variants in Patients With NSCLC
    Sorscher, Steven
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (12):
  • [2] High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
    Irene Rainville
    Shanell Hatcher
    Eric Rosenthal
    Katie Larson
    Ryan Bernhisel
    Stephanie Meek
    Heidi Gorringe
    Erin Mundt
    Susan Manley
    Breast Cancer Research and Treatment, 2020, 180 : 503 - 509
  • [3] High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
    Rainville, Irene
    Hatcher, Shanell
    Rosenthal, Eric
    Larson, Katie
    Bernhisel, Ryan
    Meek, Stephanie
    Gorringe, Heidi
    Mundt, Erin
    Manley, Susan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 503 - 509
  • [4] Germline CHEK2 variants and risk of lymphoma
    Boddicker, Nicholas J.
    Mwangi, Raphael
    Robinson, Dennis P.
    Rosenthal, Allison C.
    Habermann, Thomas M.
    Feldman, Andrew L.
    Rimsza, Lisa M.
    King, Rebecca L.
    Larson, Melissa C.
    Gysbers, Brianna J.
    Ansell, Stephen M.
    Abeykoon, Jithma P.
    Nowakowski, Grzegorz S.
    Witzig, Thomas E.
    Novak, Anne J.
    Slager, Susan L.
    Cerhan, James R.
    CANCER RESEARCH, 2023, 83 (07)
  • [5] CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
    Stolarova, Lenka
    Kleiblova, Petra
    Janatova, Marketa
    Soukupova, Jana
    Zemankova, Petra
    Macurek, Libor
    Kleibl, Zdenek
    CELLS, 2020, 9 (12)
  • [6] Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes
    Bychkovsky, Brittany L.
    Agaoglu, Nihat B.
    Horton, Carolyn
    Polfus, Linda
    Richardson, Marcy E.
    Young, Colin
    Scheib, Rochelle
    Garber, Judy E.
    Rana, Huma Q.
    JAMA NETWORK OPEN, 2025, 8 (01)
  • [7] CHEK2 Founder Variants and Thyroid Cancer Risk
    Brock, Pamela
    Liynarachchi, Sandya
    Nieminen, Taina T.
    Chan, Carlos
    Kohlmann, Wendy
    Stout, Leigh Anne
    Yao, Song
    La Greca, Amanda
    Jensen, Kirk E.
    Kolesar, Jill M.
    Salhia, Bodour
    Gulhati, Pat
    Hicks, J. Kevin
    Ringel, Matthew D.
    THYROID, 2024, 34 (04) : 477 - 483
  • [8] The controversial association of CHEK2 pathogenic variants and colorectal cancer susceptibility
    Freitas, P.
    Melo, M.
    Luis, A.
    Bento, S.
    Fernandes, S.
    Santos, S.
    Fragoso, S.
    Duarte, T.
    Rodrigues, P.
    Vaz, F.
    Miguel, I.
    ANNALS OF ONCOLOGY, 2022, 33 : S342 - S342
  • [9] Biallelic Pathogenic Variants in CHEK2 Predispose to Multiple Primary Tumours
    Stankovic, Snezana
    Vos, Janet
    van der Post, Rachel
    Brugnoletti, Fulvia
    Koene, Saskia
    Schuurs-Hoeijmakers, Janneke
    Hilhorst, Bianca
    Vreede, Lilian
    Evans, D. Gareth
    Wimmer, Katharina
    Volk, Alexander
    de Putter, Robin
    Soikkonen, Leila
    Mensenkamp, Arjen
    Genuardi, Maurizio
    Ligtenberg, Marjolijn
    Hoogerbrugge, Nicoline
    De Voer, Richarda
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 549 - 549
  • [10] Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk
    West, Allison H.
    Blazer, Kathleen R.
    Stoll, Jessica
    Jones, Matthew
    Weipert, Caroline M.
    Nielsen, Sarah M.
    Kupfer, Sonia S.
    Weitzel, Jeffrey N.
    Olopade, Olufunmilayo I.
    FAMILIAL CANCER, 2018, 17 (04) : 495 - 505
12345